A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 Over 12 Weeks in Patients With Heart Failure With Preserved Ejection Fraction

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Oct 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Praliciguat (Primary)
Indications Heart failure
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms CAPACITY-HFpEF
Sponsors Ironwood Pharmaceuticals

Most Recent Events

30 Oct 2019 According to a Cyclerion Therapeutics Media release, company will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the topline results from the Phase 2 proof-of-concept studies of praliciguat.
30 Oct 2019 According to a Cyclerion Therapeutics Media release, full results will be presented at future medical meeting.
30 Oct 2019 Results presented in a Cyclerion Media Release.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight